Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

被引：0
|
作者：
Labidi-Galy, S. I. [1 ]
Rouge, T. deLa Motte [2 ]
Derbel, O. [3 ]
Wolfer, A. [4 ]
Kalbacher, E. [5 ]
Olivier, T. [1 ]
Combes, J-D. [6 ]
Hu-Heimgartner, K. [1 ]
Tredan, O. [7 ]
Guevara, H. [7 ]
Heinzelmann-Schwarz, V. [8 ]
Fehr, M. [9 ]
de Castelbajac, V. [10 ]
Vaflard, P. [11 ]
Crivelli, L. [12 ]
Bonadona, V. [7 ]
Viassolo, V. [1 ]
Bazan, F. [13 ]
Rodrigues, M. [14 ]
Ray-Coquard, I. L. [7 ]
机构：
[1] HUG, Dept Oncol, Geneva, Switzerland
[2] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[3] Hop Prive Jean Mermoz, Inst Canc, Lyon, France
[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
[5] CHRU Besancon, Hop Jean Minjoz, Dept Oncol, Besancon, France
[6] IARC, Infect & Canc Epidemiol Grp, Lyon, France
[7] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[8] Univ Spital Basel, Dept Gynecol, Basel, Switzerland
[9] Kantonsspital Frauenfeld, Frauenklin, Frauenfeld, Switzerland
[10] Inst Curie, Dept Oncol, Paris, France
[11] Inst Curie, Dept Med Oncol, Paris, France
[12] Ctr Eugene Marquis, Div Canc Genet, Rennes, France
[13] CHU Besancon, Hop Jean Minjoz, Doubs, Besancon, France
[14] Inst Curie, Dept Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003P
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia
    Yong, Chee Meng
    Yehgambaram, Prathepamalar A. P.
    Lee, Shaun Wen Huey
    PLOS ONE, 2024, 19 (02):
  • [32] Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma
    Wagar, Matt
    Bharucha, Kharmen
    Montemorano, Lauren
    Huffman, Laura
    Godecker, Amy
    Barroilhet, Lisa
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S155 - S156
  • [33] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon J. S.
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Macpherson, Euan
    Dougherty, Brian
    Juergensmeier, Juliane M.
    Orr, Maria
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy
    Matulonis, U. A.
    Harter, P.
    Gourley, C.
    Friedlander, M.
    Vergote, I. B.
    Rustin, G. J. S.
    Fielding, A.
    Spencer, S.
    Parry, D.
    Ledermann, J. A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 8 - 8
  • [36] The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients
    Kubelac, Paul
    Vlad, Catalin
    Berindan-Neagoe, Ioana
    Irimie, Alexandru
    Achimas-Cadariu, Patriciu
    JOURNAL OF BUON, 2019, 24 (04): : 1538 - 1543
  • [37] Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
    Li, Caixia
    Ye, Wenlei
    Zhou, Wenni
    Ye, Zhikang
    Yang, Weihong
    Cheng, Zhongping
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
    Marme, F.
    Hilpert, F.
    Welslau, M.
    Grabowski, J. P.
    Schneeweiss, A.
    Hartkopf, A. D.
    Becker, S.
    Runnebaum, I.
    Bauerschlag, D.
    Fasching, P.
    Brandi, C.
    Rehbein, J-K.
    Glowik, R.
    Sehouli, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S535 - S536
  • [39] EFFICACY AND SAFETY OF MAINTENANCE OLAPARIB BY PATIENT AGE IN NON-GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER IN OPINION
    Skof, E.
    Bjurberg, M.
    Rubio Perez, M. J.
    Davidson, D.
    Blakeley, C.
    Bennett, J.
    Poveda, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A202 - A203
  • [40] Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study
    Marme, Frederik
    Hilpert, Felix
    Welslau, Manfred
    Grabowski, Jacek P.
    Schneeweiss, Andreas
    Hartkopf, Andreas D.
    Bauerschlag, Dirk
    Fasching, Peter A.
    Brandi, Christiane
    Rehbein, John-Kilian
    Glowik, Regina
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345